You're sitting on a $100,000 value investment with a cost basis likely very far north of that. It's not really the chest beater I'd lead with. I don't really care what you do with your shares. Your assessment of how easy it is to prove OS in less-aggressive cancers was deeper than wrong. It was the opposite of what you said.
Market Data 
Markets 
AI
